CREBBP and neoplasm: Furthermore, an additional pathogenic inactivating mutation was found in CREBBP (p. G757Afs*19; variant allele frequency: 24.7%).Tumor Mutational Burden was intermediate (between 6 and 19 mutations/Mb) and MSI stable (3.2%).